作者: 灰心喪氣 時間: 2025-3-21 20:58 作者: 磨碎 時間: 2025-3-22 00:46 作者: 克制 時間: 2025-3-22 05:52 作者: 脫水 時間: 2025-3-22 12:22 作者: MUTED 時間: 2025-3-22 13:29 作者: MUTED 時間: 2025-3-22 17:31
Management of Small Renal Masses,ve surveillance for select patients, and renal mass ablation, have been increasingly used. In this chapter, we review the current evidence-based papers covering aspects of the diagnosis and management of SRMs.作者: FUME 時間: 2025-3-22 23:16
The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancof non-muscle-invasive bladder cancer, discuss different risk-stratification techniques and how they can help identify those most likely to benefit from radical treatment, and examine the evidence supporting the benefit of timely cystectomy.作者: 無畏 時間: 2025-3-23 04:48
Enhanced Recovery After Surgery for Radical Cystectomy,ntributing to the morbidity of RC as possible, and optimize how patients are cared for before and after surgery. In this chapter, we review the preoperative, intraoperative and postoperative elements of using an ERAS protocol for RC.作者: SPER 時間: 2025-3-23 05:50 作者: 審問,審訊 時間: 2025-3-23 10:16
U. Wollina,M. Gebhardt,D. Lange are capable of reproducibly predicting patient outcomes. Future management of bladder cancer will likely incorporate such prognostic molecular models for risk stratification and treatment personalization.作者: Fissure 時間: 2025-3-23 15:11 作者: 多樣 時間: 2025-3-23 20:10
Molecular Prognostication in Bladder Cancer, are capable of reproducibly predicting patient outcomes. Future management of bladder cancer will likely incorporate such prognostic molecular models for risk stratification and treatment personalization.作者: Organization 時間: 2025-3-24 00:38 作者: NATTY 時間: 2025-3-24 05:46
Carmen I. Hernandez Lara BS, PhDr greater certainty for cancer control, but at the risk of significant urinary and/or sexual morbidity. Conversely, AS preserves genitourinary function and quality of life in exchange for burdensome surveillance and the psychological impact of living with cancer.作者: 陳列 時間: 2025-3-24 09:52
Miscellaneous Drug-related Adverse Effects,ous blood-based analytes, provide a method of patient evaluation with potential applications in virtually all disease states. In this review, we will describe current approaches with a particular focus on demonstrated clinical utility in the evaluation and management of prostate cancer.作者: 不真 時間: 2025-3-24 13:52 作者: 預(yù)示 時間: 2025-3-24 18:08 作者: SPURN 時間: 2025-3-24 22:18 作者: 緯線 時間: 2025-3-25 00:00
Advances in the Treatment of Metastatic Renal Cell Carcinoma,ad resurgence with the FDA approval of nivolumab with ipilimumab. In the current chapter, we attempt to contextualize available frontline therapies for metastatic renal cell carcinoma with a focus on the CABOSUN and CheckMate 214 clinical trials.作者: 胰島素 時間: 2025-3-25 04:43 作者: congenial 時間: 2025-3-25 08:09
Targeted Ablative Therapies for Prostate Cancer,treatment: active surveillance (AS) or radical therapy. This decision is further confounded by the fact that many of these men diagnosed, by an elevated PSA, will have indolent disease and never require intervention. Radical treatments, including radical prostatectomy and whole-gland radiation, offe作者: 妨礙 時間: 2025-3-25 13:54
Prostate Cancer Markers,f detecting high-grade prostate cancer. Once diagnosed, multiple markers leverage prostate cancer biopsy tissue to prognosticate clinical outcomes, including adverse pathology at radical prostatectomy, disease recurrence, and prostate cancer mortality; however the clinical utility of some outcomes t作者: FUSE 時間: 2025-3-25 18:31 作者: 繁忙 時間: 2025-3-25 20:10 作者: 安裝 時間: 2025-3-26 01:52
Advances in the Treatment of Metastatic Renal Cell Carcinoma,r (VEGF) tyrosine kinase inhibitor (TKI) therapy, the standard of care shifted to agents such as sunitinib and pazopanib. However, more recently there have been datasets, suggesting that next-generation TKIs such as cabozantinib may play an important role in therapy. Furthermore, immunotherapy has h作者: commune 時間: 2025-3-26 06:10
Optical and Cross-Sectional Imaging Technologies for Bladder Cancer,ent of non-muscle-invasive bladder cancer. In the last decade, significant technological improvements have been introduced for optical imaging to address the known shortcomings of white light cystoscopy. Enhanced cystoscopy modalities such as blue light cystoscopy and narrowband imaging survey a lar作者: maudtin 時間: 2025-3-26 08:37 作者: Foolproof 時間: 2025-3-26 13:15 作者: FLUSH 時間: 2025-3-26 19:21
Enhanced Recovery After Surgery for Radical Cystectomy,ith a high morbidity rate as well as a prolonged length of hospital stay. In recent years, there has been great interest in identifying multimodal and interdisciplinary strategies that help accelerate postoperative convalescence by reducing variation in perioperative care of patients undergoing comp作者: 險代理人 時間: 2025-3-27 00:15 作者: 親屬 時間: 2025-3-27 01:34 作者: 察覺 時間: 2025-3-27 07:14
Modern Management of Testicular Cancer,nces in surgical treatment of advanced disease has led to continued improvement in outcomes. Patients with testicular cancer who are treated following the treatment guideline mostly achieved high quality of life and long-term survival. However, patients who were identified as having non-guideline di作者: 貝雷帽 時間: 2025-3-27 11:12 作者: ACTIN 時間: 2025-3-27 17:01
Carmen I. Hernandez Lara BS, PhDtreatment: active surveillance (AS) or radical therapy. This decision is further confounded by the fact that many of these men diagnosed, by an elevated PSA, will have indolent disease and never require intervention. Radical treatments, including radical prostatectomy and whole-gland radiation, offe作者: Exuberance 時間: 2025-3-27 20:04 作者: Watemelon 時間: 2025-3-27 22:05 作者: 我要沮喪 時間: 2025-3-28 04:47
Reid A. Waldman,Jane M. Grant-Kelstion and management of SRMs have become important clinical issues. Diagnosing a mass in the early stages theoretically allows for high rates of cure but simultaneously risks overtreatment. In the past 20 years, surgical treatment of SRMs has transitioned from radical nephrectomy for all renal tumors作者: boisterous 時間: 2025-3-28 09:52
Phototherapeutic Options for Vitiligor (VEGF) tyrosine kinase inhibitor (TKI) therapy, the standard of care shifted to agents such as sunitinib and pazopanib. However, more recently there have been datasets, suggesting that next-generation TKIs such as cabozantinib may play an important role in therapy. Furthermore, immunotherapy has h作者: 攝取 時間: 2025-3-28 13:46
UV Radiation, Irradiation, and Dosimetryent of non-muscle-invasive bladder cancer. In the last decade, significant technological improvements have been introduced for optical imaging to address the known shortcomings of white light cystoscopy. Enhanced cystoscopy modalities such as blue light cystoscopy and narrowband imaging survey a lar作者: aviator 時間: 2025-3-28 17:09
U. Wollina,M. Gebhardt,D. Langeques, perioperative therapies, and postoperative management. Current management still heavily relies on pathologic staging that does not always reflect an individual patient’s risk. The genesis and progression of bladder cancer is now increasingly recognized as being a result of alterations in sever作者: FLINT 時間: 2025-3-28 20:59 作者: 柱廊 時間: 2025-3-28 23:22 作者: 腐蝕 時間: 2025-3-29 05:30 作者: 虛弱 時間: 2025-3-29 11:10
,Un h?pital pour la peau à Paris,rall survival of 14?months. Urothelial carcinomas harbor frequent molecular dysregulations including recurrent mutations and copy number alteration, some of which could be potential therapeutic targets. However, no molecularly targeted agents have been approved to date for the treatment of advanced 作者: 可互換 時間: 2025-3-29 12:48
Nuklearmedizinisch-onkologische Einführungnces in surgical treatment of advanced disease has led to continued improvement in outcomes. Patients with testicular cancer who are treated following the treatment guideline mostly achieved high quality of life and long-term survival. However, patients who were identified as having non-guideline di作者: 享樂主義者 時間: 2025-3-29 18:35 作者: Eulogy 時間: 2025-3-29 22:07
https://doi.org/10.1007/978-3-319-93339-9Genitourinary Cancers; Immunotherapy; Small Renal Masses; Molecular Prognostication; Metastatic Renal Ce作者: Diuretic 時間: 2025-3-30 00:04 作者: 攤位 時間: 2025-3-30 05:32
Genitourinary Cancers978-3-319-93339-9Series ISSN 0927-3042 Series E-ISSN 2509-8497 作者: 一美元 時間: 2025-3-30 12:07
